Cytotoxicity and metabolism of 4-methoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells

Jean L. Grem, Pamela Daychild, James Drake, Francois Geoffroy, Jane B. Trepel, Farzaneh Pirnia, Carmen J. Allegra

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We examined the cytotoxicity, biochemical effects and metabolism of 4-memethoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d] pyrimidine (MRPP), a synthetic nucleoside inhibitor of phosphoribosylpyrophosphate synthetase, in HCT 116 human colorectal cancer cells. A 4-hr exposure to 1 and 10 μM MRPP inhibited cell growth over a 72-hr period by 76 and 89%, and inhibited clonogenic capacity by 36 and 65%, respectively. MRPP was avidly metabolized to the 5′-monophosphate derivative (MRPP-MP), and MRPP-MP formation increased with increasing MRPP exposure (μM·hr). MRPP-MP was stable, and the intracellular half-life was in excess of 48 hr. A 4-hr exposure to 10 μM MRPP resulted in significant decreases in ATP, UTP, GTP, CTP, dATP, dTTP, and PRPP pools. Near maximal ribonucleotide triphosphate depletion was achieved with ≥24 μM·hr MRPP, and growth inhibition as a function of MRPP μM·hr closely reflected the biochemical effects. Ribonucleotide triphosphate pools remained depleted for up to 48 hr after drug removal, apparently as a consequence of the prolonged retention of MRPP-MP. MRPP (10 μM) inhibited the salvage of [3H]guanine, [3H]-adenine and [3H]guanosine, and concurrent exposure to MRPP and either 100 μM adenine, hypoxanthine, or guanine did not reverse ATP or GTP depletion. Concurrent exposure to 10 μM MRPP and either 10 μM adenosine, uridine or thymidine was accompanied by repletion of ATP, UTP, and dTTP pools, respectively, but depletion of other nucleotide pools was not corrected. In contrast, 10 μM guanosine did not correct GTP depletion in the presence of MRPP. The combination of 10 μM each of thymidine, uridine, adenosine and guanosine during and following a 24-hr exposure to MRPP provided partial protection against 0.1 or 1 μM MRPP, but did not affect the cytotoxicity associated with 10 μM MRPP. MRPP is a novel antimetabolite that inhibits both de novo and salvage pathways for purine synthesis and de novo pyrimidine synthesis.

Original languageEnglish (US)
Pages (from-to)2117-2126
Number of pages10
JournalBiochemical Pharmacology
Volume48
Issue number11
DOIs
StatePublished - Nov 29 1994

Fingerprint

Cytotoxicity
Metabolism
Colonic Neoplasms
Cells
Guanosine
Guanosine Triphosphate
4-methoxy-8-(ribofuranosylamino)pyrimido(5,4-d)pyrimidine
pyrimidine
Ribonucleotides
Salvaging
Uridine Triphosphate
Adenosine Triphosphate
Uridine
Guanine
Adenine
Adenosine
Thymidine
Cytidine Triphosphate
Antimetabolites
Hypoxanthine

Keywords

  • antimetabolites
  • experimental therapeutics
  • purines
  • pyrimidines

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Cytotoxicity and metabolism of 4-methoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells. / Grem, Jean L.; Daychild, Pamela; Drake, James; Geoffroy, Francois; Trepel, Jane B.; Pirnia, Farzaneh; Allegra, Carmen J.

In: Biochemical Pharmacology, Vol. 48, No. 11, 29.11.1994, p. 2117-2126.

Research output: Contribution to journalArticle

Grem, Jean L. ; Daychild, Pamela ; Drake, James ; Geoffroy, Francois ; Trepel, Jane B. ; Pirnia, Farzaneh ; Allegra, Carmen J. / Cytotoxicity and metabolism of 4-methoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells. In: Biochemical Pharmacology. 1994 ; Vol. 48, No. 11. pp. 2117-2126.
@article{7eb281ca222142609db4787fc0274288,
title = "Cytotoxicity and metabolism of 4-methoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells",
abstract = "We examined the cytotoxicity, biochemical effects and metabolism of 4-memethoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d] pyrimidine (MRPP), a synthetic nucleoside inhibitor of phosphoribosylpyrophosphate synthetase, in HCT 116 human colorectal cancer cells. A 4-hr exposure to 1 and 10 μM MRPP inhibited cell growth over a 72-hr period by 76 and 89{\%}, and inhibited clonogenic capacity by 36 and 65{\%}, respectively. MRPP was avidly metabolized to the 5′-monophosphate derivative (MRPP-MP), and MRPP-MP formation increased with increasing MRPP exposure (μM·hr). MRPP-MP was stable, and the intracellular half-life was in excess of 48 hr. A 4-hr exposure to 10 μM MRPP resulted in significant decreases in ATP, UTP, GTP, CTP, dATP, dTTP, and PRPP pools. Near maximal ribonucleotide triphosphate depletion was achieved with ≥24 μM·hr MRPP, and growth inhibition as a function of MRPP μM·hr closely reflected the biochemical effects. Ribonucleotide triphosphate pools remained depleted for up to 48 hr after drug removal, apparently as a consequence of the prolonged retention of MRPP-MP. MRPP (10 μM) inhibited the salvage of [3H]guanine, [3H]-adenine and [3H]guanosine, and concurrent exposure to MRPP and either 100 μM adenine, hypoxanthine, or guanine did not reverse ATP or GTP depletion. Concurrent exposure to 10 μM MRPP and either 10 μM adenosine, uridine or thymidine was accompanied by repletion of ATP, UTP, and dTTP pools, respectively, but depletion of other nucleotide pools was not corrected. In contrast, 10 μM guanosine did not correct GTP depletion in the presence of MRPP. The combination of 10 μM each of thymidine, uridine, adenosine and guanosine during and following a 24-hr exposure to MRPP provided partial protection against 0.1 or 1 μM MRPP, but did not affect the cytotoxicity associated with 10 μM MRPP. MRPP is a novel antimetabolite that inhibits both de novo and salvage pathways for purine synthesis and de novo pyrimidine synthesis.",
keywords = "antimetabolites, experimental therapeutics, purines, pyrimidines",
author = "Grem, {Jean L.} and Pamela Daychild and James Drake and Francois Geoffroy and Trepel, {Jane B.} and Farzaneh Pirnia and Allegra, {Carmen J.}",
year = "1994",
month = "11",
day = "29",
doi = "10.1016/0006-2952(94)90513-4",
language = "English (US)",
volume = "48",
pages = "2117--2126",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Cytotoxicity and metabolism of 4-methoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells

AU - Grem, Jean L.

AU - Daychild, Pamela

AU - Drake, James

AU - Geoffroy, Francois

AU - Trepel, Jane B.

AU - Pirnia, Farzaneh

AU - Allegra, Carmen J.

PY - 1994/11/29

Y1 - 1994/11/29

N2 - We examined the cytotoxicity, biochemical effects and metabolism of 4-memethoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d] pyrimidine (MRPP), a synthetic nucleoside inhibitor of phosphoribosylpyrophosphate synthetase, in HCT 116 human colorectal cancer cells. A 4-hr exposure to 1 and 10 μM MRPP inhibited cell growth over a 72-hr period by 76 and 89%, and inhibited clonogenic capacity by 36 and 65%, respectively. MRPP was avidly metabolized to the 5′-monophosphate derivative (MRPP-MP), and MRPP-MP formation increased with increasing MRPP exposure (μM·hr). MRPP-MP was stable, and the intracellular half-life was in excess of 48 hr. A 4-hr exposure to 10 μM MRPP resulted in significant decreases in ATP, UTP, GTP, CTP, dATP, dTTP, and PRPP pools. Near maximal ribonucleotide triphosphate depletion was achieved with ≥24 μM·hr MRPP, and growth inhibition as a function of MRPP μM·hr closely reflected the biochemical effects. Ribonucleotide triphosphate pools remained depleted for up to 48 hr after drug removal, apparently as a consequence of the prolonged retention of MRPP-MP. MRPP (10 μM) inhibited the salvage of [3H]guanine, [3H]-adenine and [3H]guanosine, and concurrent exposure to MRPP and either 100 μM adenine, hypoxanthine, or guanine did not reverse ATP or GTP depletion. Concurrent exposure to 10 μM MRPP and either 10 μM adenosine, uridine or thymidine was accompanied by repletion of ATP, UTP, and dTTP pools, respectively, but depletion of other nucleotide pools was not corrected. In contrast, 10 μM guanosine did not correct GTP depletion in the presence of MRPP. The combination of 10 μM each of thymidine, uridine, adenosine and guanosine during and following a 24-hr exposure to MRPP provided partial protection against 0.1 or 1 μM MRPP, but did not affect the cytotoxicity associated with 10 μM MRPP. MRPP is a novel antimetabolite that inhibits both de novo and salvage pathways for purine synthesis and de novo pyrimidine synthesis.

AB - We examined the cytotoxicity, biochemical effects and metabolism of 4-memethoxy-8-(β-d-ribofuranosylamino)pyrimido[5,4-d] pyrimidine (MRPP), a synthetic nucleoside inhibitor of phosphoribosylpyrophosphate synthetase, in HCT 116 human colorectal cancer cells. A 4-hr exposure to 1 and 10 μM MRPP inhibited cell growth over a 72-hr period by 76 and 89%, and inhibited clonogenic capacity by 36 and 65%, respectively. MRPP was avidly metabolized to the 5′-monophosphate derivative (MRPP-MP), and MRPP-MP formation increased with increasing MRPP exposure (μM·hr). MRPP-MP was stable, and the intracellular half-life was in excess of 48 hr. A 4-hr exposure to 10 μM MRPP resulted in significant decreases in ATP, UTP, GTP, CTP, dATP, dTTP, and PRPP pools. Near maximal ribonucleotide triphosphate depletion was achieved with ≥24 μM·hr MRPP, and growth inhibition as a function of MRPP μM·hr closely reflected the biochemical effects. Ribonucleotide triphosphate pools remained depleted for up to 48 hr after drug removal, apparently as a consequence of the prolonged retention of MRPP-MP. MRPP (10 μM) inhibited the salvage of [3H]guanine, [3H]-adenine and [3H]guanosine, and concurrent exposure to MRPP and either 100 μM adenine, hypoxanthine, or guanine did not reverse ATP or GTP depletion. Concurrent exposure to 10 μM MRPP and either 10 μM adenosine, uridine or thymidine was accompanied by repletion of ATP, UTP, and dTTP pools, respectively, but depletion of other nucleotide pools was not corrected. In contrast, 10 μM guanosine did not correct GTP depletion in the presence of MRPP. The combination of 10 μM each of thymidine, uridine, adenosine and guanosine during and following a 24-hr exposure to MRPP provided partial protection against 0.1 or 1 μM MRPP, but did not affect the cytotoxicity associated with 10 μM MRPP. MRPP is a novel antimetabolite that inhibits both de novo and salvage pathways for purine synthesis and de novo pyrimidine synthesis.

KW - antimetabolites

KW - experimental therapeutics

KW - purines

KW - pyrimidines

UR - http://www.scopus.com/inward/record.url?scp=0027973563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027973563&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(94)90513-4

DO - 10.1016/0006-2952(94)90513-4

M3 - Article

C2 - 7528507

AN - SCOPUS:0027973563

VL - 48

SP - 2117

EP - 2126

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -